Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: Week 52 results from a phase 3b, randomized, double-blind, placebo-controlled trial
J Am Acad Dermatol. 2025;92(4):816-824 doi: 10.1016/j.jaad.2024.12.018
Sofen HL, et al. present the full analysis, 52-week, results of a phase 3b, randomised, double-blind, placebo-controlled study in patients with moderate-to-severe plaque PsO affecting the scalp, demonstrating that the efficacy of tildrakizumab for the treatment of plaque PsO of the scalp, a difficult-to-treat area, is maintained long-term.
Keywords:
